Trevena Inc (TRVN) Given Average Recommendation of “Buy” by Analysts

Shares of Trevena Inc (NASDAQ:TRVN) have been given a consensus recommendation of “Buy” by the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $8.65.

A number of brokerages have recently weighed in on TRVN. HC Wainwright reduced their price target on shares of Trevena from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, October 12th. Zacks Investment Research lowered shares of Trevena from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Barclays lowered shares of Trevena from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $15.00 to $2.50 in a research note on Monday, October 16th. Needham & Company LLC cut their target price on shares of Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 8th. Finally, Oppenheimer set a $5.00 target price on shares of Trevena and gave the company a “buy” rating in a research note on Thursday, October 12th.

A number of hedge funds have recently added to or reduced their stakes in TRVN. Rhumbline Advisers lifted its stake in Trevena by 30.1% during the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 14,880 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of Trevena by 51.9% during the second quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 18,900 shares during the period. Teachers Advisors LLC raised its holdings in shares of Trevena by 26.4% during the second quarter. Teachers Advisors LLC now owns 98,153 shares of the biopharmaceutical company’s stock valued at $226,000 after acquiring an additional 20,482 shares during the period. TIAA CREF Investment Management LLC raised its holdings in shares of Trevena by 8.3% during the second quarter. TIAA CREF Investment Management LLC now owns 237,045 shares of the biopharmaceutical company’s stock valued at $545,000 after acquiring an additional 18,190 shares during the period. Finally, Nationwide Fund Advisors raised its holdings in shares of Trevena by 92.1% during the second quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 23,557 shares during the period. 56.10% of the stock is owned by institutional investors and hedge funds.

Shares of Trevena (TRVN) opened at $1.73 on Friday. The firm has a market cap of $103.27, a P/E ratio of -1.05 and a beta of -0.58. Trevena has a one year low of $1.35 and a one year high of $8.00. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.38.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.06. During the same quarter last year, the business earned ($0.57) earnings per share. research analysts anticipate that Trevena will post -1.23 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Trevena Inc (TRVN) Given Average Recommendation of “Buy” by Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/19/trevena-inc-trvn-given-average-recommendation-of-buy-by-analysts.html.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply